Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| VC1-C52H3 | Cynomolgus | Cynomolgus VCAM-1 Protein, His Tag (MALS verified) |  |
|
|
| VC1-C82E3 | Cynomolgus | Biotinylated Cynomolgus VCAM-1 / CD106 Protein, His,Avitag™ (MALS verified) |  |
|
|
| MBS-C028 | 0 | ActiveMax® VCAM-1 μBeads, premium grade (for cells, 20 μm) | |||
| MBS-C019 | Human | ActiveMax® Human VCAM-1 / CD106 μBeads, premium grade (for cells) | |||
| GMP-VC1H25 | Human | GMP Human VCAM-1 Protein, Fc Tag |  |
|
|
| VC1-H82F6 | Human | Biotinylated Human VCAM-1 / CD106 Protein, Fc,Avitag™, premium grade |  |
|
|
| VC1-H5253 | Human | Human VCAM-1 / CD106 Protein, Fc Tag, premium grade |  |
|
|
| VC1-H5224 | Human | Human VCAM-1 / CD106 Protein, His Tag (MALS verified) |  |
|
|
Immobilized Human VCAM-1 Protein, Fc Tag, premium grade (Cat. No. VC1-H5253) at 5 μg/mL (100 μL/well) can bind Human ITGA4&ITGB1 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT1-H52W1) with a linear range of 0.039-0.625 μg/mL (QC tested).
The purity of Biotinylated Human VCAM-1, Fc,Avitag, premium grade (Cat. No. VC1-H82F6) is more than 90% and the molecular weight of this protein is around 230-260 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Tocopherol acetate | DSE-9912 | Approved | National Institute Of Diabetes And Digestive And Kidney Diseases | Ephynal, Aquasol E | Mainland China | Basf Health & Nutrition As, Basf (China) Co Ltd Beijing Office | 2006-12-05 | Non-alcoholic Fatty Liver Disease; Venous Thromboembolism; Atherosclerosis; Intermittent Claudication; Thrombosis; Diabetic Retinopathy | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| 99mTccAbVCAM1‐5 | 99mTccAbVCAM1‐5 | Phase 1 Clinical | Medico-Economic Evaluation Unit , University Hospital, Grenoble | Atherosclerosis | Details |
This web search service is supported by Google Inc.
A-Z
